CTOs on the Move

Mortara Instrument

www.mortara.com

 
Founded in 1982 by David W. Mortara, PhD, Mortara Instrument was born with a guiding philosophy: design to a need, keep it simple, and make it economically accessible. Building on this philosophy, Mortara Instrument has created a complete line of
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mortara.com
  • 7865 N 86th St
    Milwaukee, WI USA 53224
  • Phone: 414.354.1600

Executives

Name Title Contact Details

Similar Companies

Sgarlato Laboratories

Sgarlato Laboratories, Inc. is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MyLife Franchise Corporation

MyLife Franchise Corporation is a Portsmouth, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vermillion

Vermillion`s vision is to become a recognized leader in the advancement of women`s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases. We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.

Zimmer MedizinSystems

Zimmer MedizinSystems is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seno Medical Instruments

Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging. Seno`s Imagio breast imaging system fuses opto-acoustic technology with ultrasound to generate functional and anatomical images of the breast. The opto-acoustic images provide a unique blood map in and around suspicious breast masses while the ultrasound provides a traditional anatomic image. Through the appearance or absence of the two hallmark indicators of cancer – angiogenesis and deoxygenation – Seno believes that the Imagio OA breast imaging system will be a more effective tool to help radiologists confirm or rule out malignancy than current diagnostic imaging modalities – without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents.